NYSE:LLYPharmaceuticals
Eli Lilly (LLY) Launches Kisunla As It Expands Its Neuroscience Push
Eli Lilly launched its FDA approved Alzheimer's drug Kisunla, adding a new treatment option to its neuroscience portfolio.
The company is preparing prominent presentations at the 2026 Alzheimer's Association International Conference, highlighting its neuroscience pipeline.
Eli Lilly is maintaining a leadership role in the AI driven Illumina Billion Cell Atlas alliance focused on large scale neurodegenerative research.
Eli Lilly (NYSE:LLY) is drawing attention for activity beyond its GLP 1...